You are here

Funding

CRT can propel promising research to the next stage by helping scientists access appropriate translational funding and 'in-kind' support. In 2015/16, CRT leveraged £29m in industry and external grant support for CRUK researchers.

  • CRUK FUNDING

    CRT Business Development Managers can provide support for researchers applying for a Cancer Research UK drug discovery project grant.

    Project grant applications in drug discovery are assessed by the Drug Discovery Expert Review Panel (DDERP), a sub-panel of the CRUK Science Committee. The Drug Discovery Expert Review Panel will consider project grant applications that directly develop research for patient benefit, improving the likelihood of research eventually leading to a new preventative, therapeutic or biomarker entity by:

    • Establishing a project plan, which charts a route to developing research findings.
    • Funding of the project plan to achieve specific milestones and endpoints.
    • Management and monitoring of the project by the charity and CRT to achieve goals within agreed timescales.

     

    Related links

  • CRT PIONEER FUND

    The CRT Pioneer Fund (CPF) is a £50 million joint initiative between CRT and the European Investment Fund (EIF) established to bridge the funding gap between drug discovery and early clinical development. The fund invests in early drug discovery projects to seamlessly take them to the end of Phase 1 before licensing to pharma for onward development. It is managed by Sixth Element Capital.

    The CPF invests directly into projects rather than infrastructure, management or company spin-outs. Two thirds of the sums invested are to go to projects sourced from Cancer Research UK funded research. In April 2013, the CPF made its first investment in a collaboration with the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, to develop a promising class of drugs called MPS1 inhibitors to treat cancer.

    For more information, contact your CRT Business Development Manager or email enquiries@cancertechnology.com.

  • CRT PROJECT DEVELOPMENT FUND

    CRT believes that rapid access to ‘kick-start’ or bridging funding is sometimes required by projects in order for them to progress to the next stage, where they may attract further substantial funding or partnering interest. Through the CRT Project Development Fund, limited sums can be granted to projects to help bridge this gap.

    In order to qualify, proposals should have a clearly defined end point which is achievable in the short to medium term. Proposals are not restricted by type but must be consistent with CRT’s vision and purpose.

    For more information, contact your CRT Business Development Manager or email enquiries@cancertechnology.com

CRUK FUNDING Open

CRT Business Development Managers can provide support for researchers applying for a Cancer Research UK drug discovery project grant.

Project grant applications in drug discovery are assessed by the Drug Discovery Expert Review Panel (DDERP), a sub-panel of the CRUK Science Committee. The Drug Discovery Expert Review Panel will consider project grant applications that directly develop research for patient benefit, improving the likelihood of research eventually leading to a new preventative, therapeutic or biomarker entity by:

  • Establishing a project plan, which charts a route to developing research findings.
  • Funding of the project plan to achieve specific milestones and endpoints.
  • Management and monitoring of the project by the charity and CRT to achieve goals within agreed timescales.

 

Related links

CRT PIONEER FUND Open

The CRT Pioneer Fund (CPF) is a £50 million joint initiative between CRT and the European Investment Fund (EIF) established to bridge the funding gap between drug discovery and early clinical development. The fund invests in early drug discovery projects to seamlessly take them to the end of Phase 1 before licensing to pharma for onward development. It is managed by Sixth Element Capital.

The CPF invests directly into projects rather than infrastructure, management or company spin-outs. Two thirds of the sums invested are to go to projects sourced from Cancer Research UK funded research. In April 2013, the CPF made its first investment in a collaboration with the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, to develop a promising class of drugs called MPS1 inhibitors to treat cancer.

For more information, contact your CRT Business Development Manager or email enquiries@cancertechnology.com.

Related links

CRT PROJECT DEVELOPMENT FUND Open

CRT believes that rapid access to ‘kick-start’ or bridging funding is sometimes required by projects in order for them to progress to the next stage, where they may attract further substantial funding or partnering interest. Through the CRT Project Development Fund, limited sums can be granted to projects to help bridge this gap.

In order to qualify, proposals should have a clearly defined end point which is achievable in the short to medium term. Proposals are not restricted by type but must be consistent with CRT’s vision and purpose.

For more information, contact your CRT Business Development Manager or email enquiries@cancertechnology.com